A study carried out through the use of systems biology, with the analysis of complex data, starting with omics data and using integrative tools for the analysis of dynamic and modular responses, has identified a candidate target and the use of its inhibitor as new useful drug to combat Alzheimer's disease. The present invention refers to the total or partial inhibition of the expression of the localized gene, or of the activity of the enzyme encoded by said gene, to be used for the treatment of Alzheimer's disease.
Alzheimer's disease is recognized as one of the most important medical-social problems that affects our society and whose treatment is, to date, fundamentally symptomatic. The drugs currently used usually improve neuropsychiatric symptoms, such as agitation or depression that appear during the evolution of the disease, and although they improve the quality of life of the patient and their close environment for a time, they do not effectively modify the cognitive deterioration that accompanies the evolution of the disease.
In the present study, through the use of systems biology, with the analysis of complex data, starting with omics data and using integrative tools for the analysis of dynamic and modular responses, a candidate target and the use of its inhibitor have been identified as new useful drug to fight Alzheimer's disease.
This inhibitor was tested in an Alzheimer model of Caenorhabditis elegans, showing a significant improvement in the phenotype and indicating its use as a new drug for the treatment of this disease. This candidate drug has been widely used in humans for the treatment of cancer, but in the quantities tested it did not exert a significant effect on the cell cycle, nor did it affect cell viability in vitro when analyzed in the microglia cell line, therefore the Reuse of this drug is presented as an effective method for the treatment of neurodegenerative diseases and a promising candidate for reuse in Alzheimer's disease.
Current development status
Experimental technologies
Applications
Applications in the field of health sciences, specifically in the therapeutic area. Candidates for drugs for the treatment of Alzheimer's disease.
Desired business relationship
Patent licensing
Technology development
The University of Malaga (UMA) is a public institution, which promotes outstanding research and teaching within the European Higher Education Area. UMA is one of the most dynamic and fast growing research and education institutions in Spain.
Create your free account to connect with OTRI-Universidad de Málaga and thousands of other innovative organizations and professionals worldwide
Send a request for information
to OTRI-Universidad
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
